EGFR E709_T710>D

CI-VAR-00000817Explore in graph →CIViC 1577

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Lung Adenocarcinoma1
EGFR E709_T710>D	Erlotinib	Predictive	C	Supports Sensitivity Response	—	submitted	EID4663 In a stage IV lung adenocarcinoma patient with EGFR E709_T710>D mutation, EGFR E709_T710>D was reported to be sensitive to erlotinib treatment. The patient was treated with erlotinib monotherapy and a… (full text at CIViC) PMID 22982663 · Ackerman et al., 2012 · Open in CIViC	civic
Lung Non-Small Cell Carcinoma1
EGFR E709_T710>D	Gefitinib	Predictive	C	Supports Sensitivity Response	2	submitted	EID3793 In a study, 2 participants with stage IV lung adenocarcinoma were sequenced at EGFR exons 18 to 21. Both patients were found to have DelE709-T710 insD mutation and were treated with the 1st generatio… (full text at CIViC) PMID 21531810 ·

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.